MARKET

IRWD

IRWD

Ironwood Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.87
-0.22
-2.18%
After Hours: 9.87 0 0.00% 16:00 04/01 EDT
OPEN
9.79
PREV CLOSE
10.09
HIGH
10.15
LOW
9.38
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
14.10
52 WEEK LOW
7.91
MARKET CAP
1.56B
P/E (TTM)
26.28
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IRWD stock price target is 14.00 with a high estimate of 18.00 and a low estimate of 12.00.

EPS

IRWD News

More
  • Ironwood Pharmaceuticals Provides Update on Impact of COVID-19
  • Business Wire · 6d ago
  • Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?
  • Zacks · 03/14 16:30
  • Ironwood Pharmaceuticals (IRWD) Presents At Barclays Global Healthcare Conference - Slideshow
  • Seeking Alpha - Article · 03/13 18:33
  • Breathe - Here Are The Best Stocks To Buy Now
  • Seeking Alpha - Article · 03/12 18:50

Industry

Biotechnology & Medical Research
-4.35%
Pharmaceuticals & Medical Research
-2.95%

Hot Stocks

Symbol
Price
%Change

About IRWD

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
More

Webull offers kinds of Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ:IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions.